Levosimendan is an inodilator developed for intravenous use in hospitalised patients with acutely decompensated heart failure (ADHF). The pharmacological effects of levosimendan are: a) increased cardiac contractility mediated by calcium sensitisation of troponin C
Side Effects:
Common adverse drug reactions (1% of patients) associated with levosimendan therapy include: headache, hypotension, arrhythmias (atrial fibrillation, extrasystoles, Atrial tachycardia, ventricular tachycardia), myocardial ischaemia, hypokalaemia and/or nausea
We are leading Exporter of Levosimendan Lyophilized Injection.
WHITE SWAN PHARMACEUTICAL
All Rights Reserved.(Terms of Use) Developed and Managed by Infocom Network Private Limited. |